8/27/2013

The FDA has granted Ceptaris Therapeutics approval to market its Valchlor gel for treatment of patients with stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma who previously received skin-directed treatment. The approval makes Valchlor gel the only FDA-cleared formulation of mechlorethamine, or nitrogen mustard.

Related Summaries